DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bococizumab
Bococizumab
Us 2018 / 0296525 A1
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
PCSK9 Inhibitors – Clinical Applications
A61p1/16 (2006.01) A61p3/00 (2006.01) Km, Ml, Mr, Ne, Sn, Td, Tg)
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
Articles Article: Non-Statin Treatments for Managing LDL Cholesterol and Their Outcomes Download
Multi-Country Non-Interventional Study on the Effectiveness and Safety of Empagliflozin in Adult Patients with Type 2 Diabetes in Europe and Asia
Stembook 2018.Pdf
Perspectives in Lipid Lowering Therapy. New Therapies Targeting Ldl – Cholesterol
Bococizumab for Primary Hyperlipidaemia and Mixed Dyslipidaemia – Adjunctive to Statin Therapy And/Or Diet
New Approaches to Lipid Modification
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Study Protocol
Atorvastatin)
PCSK9 Inhibition: the Way Forward in the Treatment of Dyslipidemia Robert M
PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients
Top View
Pharmaceutical Strategies for Reducing LDL-C and Risk of Cardiovascular Disease T
• at the Conclusion of This Program the Attendee Will: –Differentiate Lipid Management from Cardiovascular Risk Reduction
Bococizumab for the Treatment of Hypercholesterolaemia Nicola Ferria, Alberto Corsinib,C, Cesare R
Bococizumab for the Treatment of Hypercholesterolaemia Nicola Ferria, Alberto Corsinib,C, Cesare R
Long-Term Efficacy and Safety of Evolocumab in Patients With
Pharmacologic Therapies
WO 2015/150995 Al 8 October 2015 (08.10.2015) P O P C T
Bococizumab Product Analysis
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9
Lipid-Reduction Variability and Antidrug-Antibody Formation With
(12) United States Patent (10) Patent No.: US 9.458,168 B2 Trzupek Et Al
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
2020 Annual Report Will Be Remembered As the Year Everything Changed
HDL As Therapeutic Target
Early Prevention of Atherosclerosis: Detection and Management of Hypercholesterolaemia in Children and Adolescents
Efficacy and Safety of Bococizumab (RN316/PF-04950615)
(INN-Nimet) 8.12.2020
Accumulating Clinical Data on PCSK9 Inhibition: Key Lessons and Challenges
Vazkepa , INN-Icosapent Ethyl
PCSK9 Inhibition: a Promise Fulfi Lled?
Review Article Cardiovascular Outcomes of PCSK9 Inhibitors: with Special Emphasis on Its Effect Beyond LDL-Cholesterol Lowering
A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
FUTURE TREATMENTS the Future of Treatment Options for Dyslipidemia Will Most Likely Involve the Evaluation of Other Parameters Besides LDL-C
Update on PCSK9 Inhibitors Kathleen H
Managing Hyperlipidaemia in Patients with COVID-19 and During Its Pandemic: an Expert Panel Position Statement from HEART UK